Body Shortcuts
R&D JW, leading global new drug development
Home

Research Pipeline

  • Discovery
  • Lead optimization
  • Pre-clinical
  • Phase Ⅰ
  • Phase II
  • Phase III
  • Registration
Category Code name Development phase Being in adjustment
NBE CreaVaX-HCC
 
 
 
 
 
 
  Liver cancer (for surgical patients)
CreaVax-HCC
 
 
 
 
 
    Liver cancer (targeted at carotid chemistry and color transmutation patients)
CreaVax-BC
 
 
 
 
 
    glioblastoma

CreaVax-HCC

Summary of Phase II clinical trial

  1. CreaVax-HCC was well tolerated to firstly diagnosed early HCC patients.
  2. CreaVax-HCC showed significant inhibition of tumor recurrence with curative hepatic resection suggesting increase of recurrence free survival in two years

Summary of Phase III clinical trial

  1. Study design : A Multi-centered, randomized, double-blind, placebo-controlled Phase III study on the efficacy and safety of CreaVax-HCC in patients with hepatocellular carcinoma for comparing after curative hepatic resection
  2. Target patients : Early HCC patients after curative hepatic resection with CR confirmation (n=166)
  3. Current state : Completion of Enrollment